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Introduction 
Electroconvulsive therapy (ECT) is an effective and safe treatment option for specific forms of 
depression, such as treatment-resistant depression, psychotic depression or melancholia in 
both, uni- and bipolar affective disorder [1, 2], with response rates usually ranging around 70%. 
Despite this remarkable efficacy even in highly treatment-resistant depression, there is still a 
considerable group of non-responders to ECT. Therefore, it is of high clinical interest to identify 
factors or markers that could provide information prior to treatment on whether the individual 
patient will respond to ECT or not.   
Previous studies have provided a large body of evidence about potentially prognostic 
demographic or clinical factors such as age, bipolarity, family history of depression or comorbid 
axis II disorder that might contribute to the risk of non-response to ECT [3, 4]. Others tried to 
elucidate whether a set of ictal parameters might predict the clinical outcome [5, 6]. More 
recently, several imaging markers were successfully used to predict the outcome to ECT in 
major depression, for example the baseline level of higher BOLD signal fluctuations of the 
subcallosal cingulate cortex [7], the subgenual cingulate volume [8] and several gray matter 
regions [9].  
A few blood-based candidate biomarkers for ECT treatment response have been identified, 
including vascular endothelial growth factor [10] and homovanillic acid [11]. In contrast to 
markers from blood that might not be central nervous system (CNS)-specific, markers 
measured in the cerebrospinal fluid (CSF) could reflect cerebral processes much more directly. 
However, biomarkers in the CSF that could predict outcome to ECT in patients with major 
depression have not been identified yet. 
We recently ran a study in which CSF samples before and after a course of ECT in patients 
with severe depression were collected. Thus, we had the opportunity to analyse several 
markers from different areas, such as lipids (endocannabinoids and sphingolipids), cytokines, 
elements from the kynurenine pathway and different markers of neurodegeneration. In this 
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study, we analysed these biomarkers in patients with depression to examine if there were 
correlations of their baseline CSF levels before ECT with the clinical outcome of ECT. 
Methods 
Patients 
Our prospective study was approved by the appropriate ethics committee and was performed 
in accordance with The Code of Ethics of the World Medical Association (Declaration of 
Helsinki). Written informed consent was obtained from all participants before enrolment. The 
study took place from 2012 to 2014 at the Department of Psychiatry at the Central Institute of 
Mental Health in Mannheim, Germany. Inclusion criteria were a present treatment resistant 
depressive episode (defined as failure to achieve response or remission to at least two proven 
antidepressant trial with adequate dosing and duration [12]) within the context of a diagnosis 
of either major depressive disorder or bipolar disorder according to DSM-IV, age above 18 
years and the clinical decision for an ECT treatment. Exclusion criteria were substance-related 
disorders including tobacco and alcohol, the lifetime diagnosis of schizophrenia, any signs of 
an on-going inflammation process such as leucocytosis, elevated acute phase proteins or 
fever, the intake of any medication with known immunomodulatory properties such as non-
steroidal anti-inflammatory drugs or glucocorticoids and the reported use of Δ9-
tetrahydrocannabinol (THC) twelve months before the study or detection of THC in urine drug 
screen. The patients continue their prior psychotropic medication during the ECT treatment. 
The Hamilton Depression Rating Scale (HDRS; 21 items version) was used to assess the 
severity of depression before and after the ECT in each patient. Response was defined as a 
reduction of at least 50% in symptoms measured by the HDRS. The Mini-Mental-State 
Examination (MMSE) was used to assess the gross cognitive performance prior to treatment. 
ECT treatment 
Right unilateral brief pulse ECT was performed with a Thymatron IV device (Somatics, LLC. 
Lake Bluff, IL, USA), s-ketamine was used as the anaesthetic substance (~1.0 mg/kg) [13, 14] 
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and succinylcholine for muscle relaxation (~1.0 mg/kg). Seizure threshold in all patients was 
titrated at the initial session and dosing at subsequent treatments was given at > 2.5 times 
threshold. The energy was subsequently increased if patients did not respond clinically or if 
seizures were insufficient during the ECT course. Two or three ECT sessions per week were 
performed. All patients started with unilateral stimulation, in the case of non-response, it was 
possible to switch to bilateral stimulation as a decision of the ECT supervisor.   
Sampling 
Before the first ECT session and between one and seven days after the last ECT session, all 
CSF samples were drawn at around 9:00 am. The patients were in a non-fasting status. They 
had a light breakfast at 8:00 am. Lumbar punctures were performed in the sitting position 
according to standardized procedure. All samples were taken, aliquoted and transferred at    -
80°C within 30 min either in glass vials (Hycultec, Beutelsbach, Germany) for the analyses of 
the lipids, in polypropylene tubes for the analyses of the markers of neurodegeneration or in 
protein LoBind tubes (Eppendorf, Germany) for all other substances. The samples were stored 
at -80°C and were never thawed or refrozen prior to the presented analyses.  
CSF and serum laboratory analyses 
Baseline and follow-up samples were analyzed on one occasion on the same plates using the 
same batch of reagents. 
Tau proteins and β-amyloids 
All samples were measured at the National TSE (Transmissible Spongiform 
Encephalopathies) Reference Centre (Göttingen, Germany). CSF levels of Aβ1-40, Aβ1-42, total 
tau and its phosphorylated isoform were determined with commercially available enzyme-
linked immunosorbent assay (ELISA) kits, described elsewhere [15].  
Neurogranin 
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All samples were measured at the Clinical Neurochemistry Laboratory at Sahlgrenska 
University Hospital. CSF Ng concentration was measured by enzyme-linked immunosorbent 
assay (ELISA), essentially as described [16], using the anti-Ng antibody pair Ng2 and Ng22. 
Intra-assay coefficients of variation were below 10%.  
Endocannabinoids 
All samples were measured at the Lipidomics/Mass Spectrometry Facility at the Institute for 
Physiological Chemistry at the University Medical Center Mainz. Endocannabinoids were 
qualitatively and quantitatively analyzed using liquid chromatography/ multiple reaction 
monitoring (LC/MRM) according to the procedures described elsewhere [17]. Levels of both 
AEA and 2-AG were measured, as well as levels of arachidonic acid (AA), from which both 
endocannabinoids are derived. 
Elements of the innate immune system  
CSF concentrations were measured as instructed by the manufacturer, using sandwich ELISA 
kits for interleukin-6 (IL-6), neopterin, soluble CD14 (sCD14), soluble CD163 (sCD163), 
macrophage migration inhibitory factor (MIF) and monocyte chemotactic protein 1 (MCP-1) as 
described elsewhere [18]. 
Metabolites of the Kynurenine Pathway 
CSF levels of kynurenine (KYN), kynurenic acid (KYNA), picolinic acid (PIC), quinolinic acid 
(QUIN), tryptophan (TRY), 3-hydroxykynurenine (3-HK) were determined using a high-
performance liquid chromatography kit. For further details see Supplementary Methods. From 
these values, the kynurenine-to-tryptophan ratio (KYN/TRY) was calculated. 
Sphingolipids 
BESCHREIBUNG AUS HEIDELBERG FEHLT NOCH 
sKlotho 
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All samples were measured at the Department of Pediatric Kidney, Liver and Metabolic 
Diseases, Hannover Medical School, Hannover, Germany. The concentration of Klotho in CSF 
was quantified using a human Klotho enzyme-linked immunosorbent assay (ELISA) kit 
measuring the entire soluble α-Klotho protein secreted in the systemic circulation after its 
release from the cell membrane via shedding (cleaved Klotho) or alternative splicing (secreted 
Klotho) with an assay sensitivity of 6.15 pg/mL (Immuno-Biological Laboratories Co., Ltd., 
Gunma, Japan).  
Statistical analyses 
Statistics were performed using STATA® (StataCorp, Texas 77845, USA, version 11) at a 
significance level ≤ 0.05. Normality was examined using the Shapiro-Wilk and data were log-
transformed when necessary. No correction for multiple testing was performed to avoid type II 
errors in this study with its small sample size. In line with that, results with significance levels 
between 0.05 and 0.1 were additionally reported as trend observations. Spearman's 
correlation (rs) was used to determine the strength and direction of the relationship between 
the concentration of the different markers and either the extent of depressive symptoms at 
baseline or the reduction of depressive symptoms during ECT or possible moderators. Linear 
regression was used to estimate which single marker could predict the reduction of the HDRS 
score during ECT and multiple regression analysis with stepwise inclusion was used to identify 
models, in which more than one marker could add significantly to the prediction. Group 
differences between responder and non-responder were examined with the Wilcoxon rank-
sum test. Logistic regression (responder vs. non-responder) was not be performed due to the 
small sample size. 
Results 
We included 12 patients into the study, who underwent a completed course of ECT and lumbar 
puncture before and thereafter. In general, ECT was effective with a reduction of the mean 
initial HDRS from 29.9 ±6.6 to 9.0 ±5.2 after the final session (p<0.001). Ten patients (83.3%) 
could be classified as treatment responder, whereas two patients (16.7%) were considered as 
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non-responders to ECT. Three patients (two females, one male, mean age: 75.7 ±6.4) had the 
clinical diagnosis of an Alzheimer’s disease (AD) additional to their current severe depressive 
episode. Demographic and clinical features are shown in Table 1. 
Absolute reduction of depressive symptoms 
CSF baseline levels of AEA (rs=0.65; p=0.029), Aβ1-40 (rs=0.64; p=0.025), tau protein (rs=0.68; 
p=0.015) and its phosphorylated isoform (rs=0.58; p=0.049), Ng (rs=0.64; p=0.024), sCD14 
(rs=0.82; p=0.0021), KYN (rs=0.64; p=0.036) and KYN/TRY (rs=0.63; p=0.038) positively 
correlated with the absolute reduction of depressive symptoms during ECT. At trend level, we 
found this correlation also for CSF levels of IL-6 (rs=0.56; p=0.072), neopterin (rs=0.54; 
p=0.087), sCD163 (rs=0.54; p=0.084), PIC (rs=0.68; p=0.062), QUIN (rs=0.67; p=0.070), 
phosphatidylcholines (rs=0.58; p=0.080) and the total amount of sphingolipids (rs=0.58; 
p=0.080) (Figure 1-4). Age (p=0.79), MMSE at baseline (p=0.39), clinical AD diagnosis 
(p=0.12) and sex (p=0.44) were not associated with reduction of depressive symptoms during 
ECT. A summary of the significant findings is presented in Table 2. 
Linear regression models established that all, sCD14 (F(1, 9)=18.91; p=0.002) , tau (F(1, 
10)=9.3; p=0.013)  and its phosphorylated isoform (F(1, 10)=9.49; p=0.012)  (Figure x) could 
statistically significantly predict the absolute reduction of depressive symptoms. However, no 
multiple regression model could be found that predicted this absolute reduction better than any 
single marker in the linear regression analyses. 
Relative reduction of depressive symptoms 
Correlations with the relative reduction of depressive symptoms during ECT were found for 
sCD14 (rs=0.65; p=0.032), PIC (rs=0.79; p=0.021) and KYN (rs=0.61; p=0.047) and additional 
for KYNA (rs=0.54; p=0.086) and the kynurenine-to-tryptophan ratio (rs=0.56; p=0.076) at a 
statistical trend level of significance. We found no correlation with potential confounders such 
as age (p=0.51), MMSE at baseline (p=0.49) or the clinical AD diagnosis (p=0.33). However, 
at trend level, females had a higher relative HDRS reduction by ECT than men (p=0.057). 
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A linear regression model established that PIC (F(1, 6)=6.56; p=0.043) could statistically 
significantly predict the absolute reduction of depressive symptoms. Additionally, combining 
PIC and KYN in a multiple regression model predicted the relative reduction of depressive 
symptoms with both variables added statistically significantly to the prediction (F(1, 9)=27.8; 
p=0.0020).  
Responders vs. Non-Responder  
We found a difference in the baseline CSF levels of KYN (z=2.1; p=0.034) in responders 
compared to those patients, who did not show a response to the treatment. At trend level, we 
found this correlation also for CSF levels of neurogranin (z=2.0; p=0.052), tau protein (z=1.7; 
p=0.086) and its abnormal phosphorylated isoform (z=2.0; p=0.052), sCD163 (z=1.7; 
p=0.099), kynurenic acid (z=1.7; p=0.096) and PIC (z=1.7; p=0.096). Age (p=0.39), MMSE at 
baseline (p=1.00), the clinical AD diagnosis (p=0.42) or sex (p=0.33) were not associated with 
the outcome parameter “response to ECT”, defined as a reduction of at least 50% in symptoms 
measured by the HDRS. 
Discussion 
This is the first study that estimated the antidepressant therapy-outcome of ECT based on 
biomarker profiles in CSF at baseline, which could be a very interesting approach for future 
applications of biomarkers. We found a variety of markers from different areas that were 
correlated with either absolute or relative reduction of the HDRS that could be observed during 
a course of ECT or with the status responders vs. non-responders after ECT.  
Markers of neurodegeneration, the innate immune system and metabolites of the kynurenine 
pathway were those that correlated the most with the antidepressant efficacy. In terms of 
neurodegeneration tau protein, its abnormal phosphorylated isoform, Aβ1-40 and neurogranin, 
all known to be highly correlated or associated with each other [19] were correlated with any 
form of therapeutic effect, independent of confounders such as age or the presence of a clinical 
diagnosis of AD. A similar relationship between those markers and response to any 
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antidepressant efficacy has not been reported yet and should be investigated in more detail in 
future studies. The baseline CSF concentrations of the metabolites of the kynurenine pathway, 
KYN, KYNA, the kynurenine-to-tryptophan ratio, PIC and QUIN were all positively correlated 
with the antidepressant effect of the ECT in those severely depressed patients. These findings 
are in general in line with the proposed involvement of the kynurenine pathway in depression 
[20-22]. Concerning the response to ECT, two recent studies that analysed the possible 
correlation to tryptophan metabolites in plasma did not observe such a correlation [23, 24], but 
no such studies has been carried out with analysis of the CSF, yet. Based on the relative 
abundance on the relationship between the immune system and different aspects of 
depression [25-27], it is not surprising that the baseline CSF levels of sCD14 and to a lesser 
extent of IL-6, neopterin and sCD163 - all involved primarily in the innate immune response 
[18] were positively correlated with the antidepressant outcome of ECT. Interestingly those 
three complex systems are tightly associated with each other: Changes of (p-)tau protein and 
Aβ within Alzheimer’s disease (AD) are known to be associated with alterations in the 
metabolites of the kynurenine pathway [28] and inflammation [29], whereas the kynurenine 
pathway links inflammation and the immune system to the pathophysiology of depression [21, 
30, 31] and inflammation is seen in both, depression and AD with dysfunctional Aβ and tau 
[32]. Our findings point towards an involvement of these complex systems in the 
antidepressant mechanism of ECT. To complement these modes to the established 
pathomechanisms of ECT, this involvement has to be explored in a more detailed way. 
For lipids, the initial CSF levels of the endocannabinoid AEA and of elements of the 
sphingolipids were associated with antidepressant efficacy during ECT. Those markers have 
not been investigated concerning the issue of antidepressant outcome prediction yet, but at 
least our group recently reported that CSF AEA levels are increased by ECT and that those 
levels were positively correlated with the number of ECT session that were performed in each 
individual patient [33]. This finding corroborates a growing body of - primarily preclinical - 
evidence that suggests an involvement of the endocannabinoid system in the pathophysiology 
of depression [34] and asks especially for more studies about the relationship between 
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depression/antidepressant action and the endocannabinoid system in human. Sphingolipids, 
especially ceramides have already been linked with depression [35, 36], thus the results at a 
trend level significance could be cautiously integrated into this concept.  
Limitations 
The small sample size is probably the major limitation of our study. The samples were taken 
from a study, in which the patients were asked to consent to lumbar puncture twice - before 
and after ECT, therefore the recruitment was extremely difficult. Nonetheless, the sample size 
was large enough to identify larger effects and at least suggesting more moderate effects as 
well. Thus, these positive results from our small sample are promising to be replicated in future 
studies. Surely, we cannot exclude that with a larger sample size, smaller effects of other 
markers could have been unveiled. A further limitation in respect to the small sample size is 
that no adjustment for possible confounders such as age, sex or BMI could be performed. 
Based on the clinical reality, the study was only possible to conduct with our patients continuing 
some of their psychotropic medication that consisted of antidepressants, antipsychotics, 
benzodiazepines and lithium during the ECT treatment. In our cases, the medication in each 
patient was at least kept constant during the ECT course. Due to the design of our study, it is 
not possible to unmask any causal relationship between ECT and the identified CSF markers 
that correlated with the antidepressant efficacy. However, it is at least tempting to assume that 
the most efficient known antidepressant biological method, namely ECT works mostly efficient, 
when biological markers that might reflect any part of the pathway of depression are abnormal.  
In summary, our CSF study was primarily meant to identify markers that indicate whether the 
therapy option of ECT in patients with severe depression might be successful. Based on these 
markers, further research regarding the mechanism of ECT and personalized antidepressant 
therapy is suggested, but of course, treatment decisions for the individual must not be made 
based on our preliminary findings. 
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Table 
Number of included subjects 12 
Age (mean) ± SD in years (min - max) 59.0 ± 21.9 (21 - 83) 
Sex female/male n/n (in %) 7/5 (58.3/41.7) 
Type of depression: unipolar/bipolar n/n (in %) 9/3 (75.0/25.0) 
Duration of current depressive episode in months, mean ± SD (min - max) 18.7 ± 21.9 (1 - 60) 
Age of onset (mean) ± SD in years (min - max) 49.2 ± 21.8 (12 - 80) 
Duration of illness in years, mean ± SD (min - max) 9.9 ± 9.1 (0.5 - 26) 
Body mass index, mean ± SD (min - max) 23.5 ± 3.5 (20 - 31) 
HDRS, sum score  
   Baseline HDRS, mean ± SD (min - max) 29.9 ± 6.6 (21 - 41) 
   Final HDRS, mean (min - max) 9.0 ± 5.2 (3 - 16) 
   Mean change ± SD (min - max) 20.9 (-6 - 36) (p<0.001) 
Numbers of ECT sessions, mean ± SD (min - max) 10.6 ±5.0 (4 - 19) 
Days between the two CSF samples, mean ± SD (min - max) 35.7 ±15.3 (17 - 59) 
Days between last ECT and 2nd sample, mean ± SD (min - max) 4.6 ±2.4 (2 - 7) 
Switch to bilateral stimulation n (in %) 3 (25) 
Remitters/Responders/Non-responders* n/n/n (in %) 5/10/2 (41.7/83.4/16.7) 
Table 1: Demographic and clinical features of the patients.  
 






















Endocannabinoids AEA - - 2-AG AA 




























Total amount of 
sphingolipids* 
Phosphatidylcholines* 
- - Ceramide Sphingomyelin 
sKlotho - - - sKlotho 
 
Table 2: Summary of the results for each category. 
*=Statistical significance at trend level (0.1>p>0.05) 
 
 
   17 
 
 
 
Figures 
IN PREPARATION 
 
